A multi-center, single arm, Phase II study of adjuvant imatinib mesylate (glivec) in patients following the resection of primary gastrointestinal stromal tumor (GIST).
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms IMAGE
- Sponsors Novartis; Novartis Pharmaceuticals
- 14 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Dec 2013 Planned end date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 22 Feb 2013 Planned end date changed from 1 Mar 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.